RxDoctor Payments DataLook up a doctor →

Dhiraj Narula, MD

Clinical Cardiac Electrophysiology · Las Vegas, NVNPI 1558399485

Payments from drug & device makers

$62,852in general payments, 2019–2025

Across 341 payments — averaging $184.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$37K
  • Cvrx, Inc.$15K
  • Medtronic$4K
  • Abbott$2K
  • Atricure, Inc.$1K
  • Novartis$517
  • plus $3K from 34 others

What the payments were for

  • Travel & lodging$4,00529%
  • Food & beverage$9,70271%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,852 in reported general payments places this provider in the 90th percentile of 20 clinical cardiac electrophysiology providers in Nevada.

See all clinical cardiac electrophysiology providers in Nevada

Medicare billing

Part B allowed, 2024
$855,349
Medicare patients
627
Services billed
7,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban211$286,181
EntrestoSacubitril/Valsartan182$235,233
XareltoRivaroxaban91$101,955
FarxigaDapagliflozin Propanediol85$83,894
Dofetilide321$59,223
MultaqDronedarone Hcl41$54,015
JardianceEmpagliflozin33$37,426
VerquvoVericiguat15$21,941
BrilintaTicagrelor12$8,577
Dabigatran EtexilateDabigatran Etexilate Mesylate15$4,367
Ezetimibe67$4,112
Ranolazine ErRanolazine28$3,390
Metoprolol Succinate216$3,252
Rosuvastatin Calcium191$2,819
Flecainide Acetate56$2,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$84$286,181211 claims
NovartisEntresto$517$235,233182 claims
Johnson & JohnsonXarelto$334$101,95591 claims
AstraZenecaFarxiga, Brilinta$14$92,47197 claims
Sanofi-aventis U.S. LLCMultaq$65$54,01541 claims
Boehringer IngelheimJardiance$22$37,42633 claims
MerckVerquvo$461$21,94115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 clinical cardiac electrophysiology providers in Nevada.

Other clinical cardiac electrophysiology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →